News

As per the agreement, Altea and KAI are expected to examine the transdermal delivery of certain Kai proprietary compounds using Altea’s transdermal delivery technology, the PassPort System. Moreover,

Additionally, Evotec is expected to provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management,

The company said that, with the installation of the new machine, it can produce cold foil blisters or thermoformed blister packages from PVC, PVDC, and barrier films such

As per the agreement, CrystalGenomics is expected to receive research funding from AstraZeneca for two years. CrystalGenomics will also be eligible to receive future milestones and royalty payments

Using Kenta’s proprietary hybridoma cell line, Rentschler will develop a manufacturing process for the former’s KBSA301 antibody using, for the first time, single-use bioreactor technology. Nikolaus Rentschler, chief

Reportedly, the APC’s team of pharmacovigilance experts provide a complete range of services using the latest technology. The service is based on a fully electronic platform which is

The decision was based on results from the clinical trial, OGT 918-007, and two multicenter NP-C disease cohort studies and clinical trials in related lysosomal storage disorders for

Franz Groiss, in-charge of managing clinical studies at Avir, said: “In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets

Sirnaomics is developing nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles, ligand-directed nanoparticles, and infrared-activated nanoparticles, for various types of therapeutic applications. Patrick Lu, president and